Salud financiera de hoja de balance de Sunzen Biotech Berhad

Salud financiera controles de criterios 5/6

Sunzen Biotech Berhad tiene un patrimonio de accionistas total de MYR138.0M y una deuda total de MYR6.7M, lo que sitúa su ratio deuda-patrimonio en 4.8%. Sus activos y pasivos totales son MYR158.6M y MYR20.6M respectivamente. El BAIT de Sunzen Biotech Berhad es de MYR12.2M, por lo que su ratio de cobertura de intereses es de 45.8. Tiene efectivo e inversiones a corto plazo que ascienden a MYR23.0M.

Información clave

4.8%

Ratio deuda-patrimonio

RM6.66m

Deuda

Ratio de cobertura de intereses	45.8x
Efectivo	RM22.98m
Patrimonio	RM137.98m
Total pasivo	RM20.65m
Activos totales	RM158.63m

Actualizaciones recientes sobre salud financiera

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Recent updates

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (MYR55.7M) de SUNZEN superan a sus pasivos a corto plazo (MYR9.9M).

Pasivo a largo plazo: Los activos a corto plazo de SUNZEN (MYR55.7M) superan a sus pasivos a largo plazo (MYR10.7M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: SUNZEN tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de SUNZEN ha crecido de 4.8% a 4.8% en los últimos 5 años.

Cobertura de la deuda: La deuda de SUNZEN está bien cubierta por el flujo de caja operativo (141.6%).

Cobertura de intereses: Los pagos de intereses de la deuda de SUNZEN están bien cubiertos por el BAIT (45.8x cobertura).

Salud financiera de hoja de balance de Sunzen Biotech Berhad

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Recent updates

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera